



## Ladislav Šenolt

Country: Czech Republic

Contact e-mail: seno@revma.cz, lsenolt@yahoo.com

Year of birth: 1976

### Main diplomas:

2001 - MD - First Faculty of Medicine, Charles University in Prague, Czech Republic  
2006 - PhD - Postgraduate Doctoral Study of Human Physiology and Pathophysiology,  
First Faculty of Medicine, Charles University in Prague, Czech Republic  
2008 - Board certification in rheumatology - Institute of Rheumatology, Prague, Czech Republic

### Current position and hospital/university:

2006 – present: Senior Lecturer and Consultant in Rheumatology, Institute of Rheumatology,  
Department of Rheumatology of the First Faculty of Medicine, Charles  
University in Prague, Czech Republic

2006 – present: Head of Connective Tissue Research Laboratory, Institute of Rheumatology,  
Prague, Czech Republic

2009 – Associate Professor of Internal Medicine, First Faculty of Medicine, Charles  
University in Prague, Czech Republic

### Position within EULAR/international experience:

EMEUNET member

### International experience:

2004-2005: Center of Experimental Rheumatology and WHO Collaborating Center for  
Molecular Biology and Novel Therapeutic Strategies for Rheumatic Diseases,  
Zürich, Switzerland

### Areas of Research/Interest:

Molecular pathogenesis of rheumatoid arthritis

The role of adipocytokines and S100 proteins in the process of joint damage and immune response

Prospective therapy for rheumatoid arthritis

### Select Publications:

1. **Senolt L**, Vencovský J, Pavelka K, Ospelt C, Gay S. Prospective new biological therapies for rheumatoid arthritis. *Autoimmun Rev.* 2009;9:102-7.
2. Pavelka K, Jarosová K, Suchý D, **Senolt L**, Chroust K, Dusek L, Vencovský J. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. *Ann Rheum Dis.* 2009;68:1285-9.
3. **Senolt L**, Housa D, Vernerova Z, Jirasek T, Svobodova R, Veigl D, Anderleova K, Muller-Ladner U, Pavelka K, Haluzik M. Resistin is abundantly present in rheumatoid arthritis synovial tissue, synovial fluid, and elevated serum resistin reflects disease activity. *Ann Rheum Dis* 2007;66:458-63.
4. Klingelhofer J, **Senolt L**, Baslund B, Nielsen GH, Skibshoj I, Pavelka K, Neidhart M, Gay S, Ambartsumian N, Hansen BS, Petersen J, Lukanidin E, Grigorian M. Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: putative involvement in the pathogenesis of rheumatoid arthritis. *Arthritis Rheum.* 2007;56:779-89.
5. **Senolt L**, Grigorian M, Lukanidin E, Simmen B, Michel BA, Pavelka K, Gay RE, Gay S, Neidhart M. S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases. *Ann Rheum Dis.* 2006;65:1645-8.